Since CaSR activation on tumor cells promotes the secretion of PTHrP, which is also known to block OPG production [3], the fact that the neutralizing antibody targeting epiregulin does not totally block CaSR-mediated decrease in OPG expression is not surprising. This evidence concerns the gene CASR and neoplasm.